Project Grant R21TR005192
Award Date
6/5/25
Completion Date
5/31/27
Dollars Obligated
$490K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350 provides $178,000.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a bone marrow organoid system to study Runx1-Familial Platelet Disorder with Associated Myeloid Malignancy (Runx1-FPD/MM). The key objectives are to generate bone marrow organoids from human induced pluripotent stem cell lines derived from Runx1-FPD/MM patients...
This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to study the use of tyrosine kinase inhibitors as a preventive therapy for Familial Platelet Disorder (FPD), a rare inherited condition associated with a high risk of developing hematologic malignancies. The total funding amount is $485,790, with a performance period from May 1, 2025, to April 30, 2030. The project will be conducted by the...
The federal Project Grant award of $445,000.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), will support research to understand the mechanisms by which mutations in the CLPB gene lead to impaired neutrophil development and severe congenital neutropenia (SCN). The research aims to define how mitochondrial dysfunction caused by CLPB mutations leads to neutrophil precursor cell death, and how somatic RUNX1 mutations...
This $650,000 Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) will fund a 4-year clinical research study titled "PHASE 2A/2B STUDY EMAPALUMAB: A WINDOW OF OPPORTUNITY IN PEDIATRIC APLASTIC ANEMIA". The study aims to evaluate the use of the interferon-gamma neutralizing monoclonal antibody emapalumab as an upfront prophase to stratify newly diagnosed pediatric patients with aplastic anemia for personalized curative therapy. Key objectives...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 3-year, $445,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant is for a research project titled "NET STABILIZATION: MECHANISTIC AND THERAPEUTIC STUDIES STUDYING THE ROLE OF NETS IN THROMBOINFLAMMATORY DISEASE." The project aims to characterize the role of neutrophil extracellular traps (NETs) in immune...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,500 project grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to investigate clonal evolution in Fanconi anemia. The grant period runs from September 30, 2023 to September 29, 2026. As a non-profit pediatric teaching hospital and research center, Boston Children's Hospital will leverage its expertise in pediatric medicine, genomics, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $435,804 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to elucidate the mechanistic basis for the selective advantage of the acquired DDX41R525H mutation in hematopoietic stem cells (HSCs) of patients with germline DDX41 mutations, who develop myelodysplastic syndrome (MDS) and related myeloid malignancies. The...
The federal Project Grant award R01HL172489 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $2,654,903 award, with a period of performance from September 2024 to May 2028, supports the development of an alpha-retroviral vector-based platform for in vivo and ex vivo delivery of genetic therapies to hematopoietic stem cells. The research aims to enable simple, economical, and widespread application of...
This $156,136 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, aims to develop biochemical reagents and assays to analyze the structure and function of the PAX3-FOXO1 fusion protein that drives the rare disease alveolar rhabdomyosarcoma. Specifically, the project will generate recombinant PAX3-FOXO1 constructs and conduct preliminary structural screening using innovative nuclear magnetic resonance techniques. It will also establish in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $765,622 to support research into developing orally bioavailable protein degraders to treat sickle cell disease (SCD). The award aims to create small molecule degraders of two fetal hemoglobin gene repressors in order to elevate fetal hemoglobin levels and prevent red blood cell sickling, a key pathological mechanism in SCD....